Powder inhaler in which it plans to market its lead pipeline compound aclidinium bromide for chronic obstructive pulmonary disease. And will aid patient compliance with anticholinergic medication.
Director of Pharmaceutical Development Dr Carsten Consul internet marketing seo services streamit2me said the inhalation device will appeal to patients and healthcare professionals because it is small. Dose indicator flags up a red signal to warn patients when the inhaler is close to empty and the device locks out when its. The new inhaler is one of very few that ticks all the boxes for complying with international regulatory requirements. Dose combination with an inhaled corticosteroid which could be ready to file in. Company spokesmen said this week Almirall believes the new treatment aclidinium bromide has potential not only to improve on other medications of its type in relieving symptoms faster and for longer with fewer side effects.